Royalty Pharma plc

RPRX · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$464$30$433$334
Dep. & Amort.$0$0$0$0
Deferred Tax$0$0$0$0
Stock-Based Comp.$0-$1$1$1
Change in WC-$712$776-$64$52
Other Non-Cash$1,815-$379$227$356
Operating Cash Flow$640$427$596$743
Investing Activities
PP&E Inv.$1-$1$0$0
Net Acquisitions-$5-$69$0$0
Inv. Purchases$76-$75-$5-$496
Inv. Sales/Matur.$3$3$523$13
Other Inv. Act.-$975-$228-$14-$22
Investing Cash Flow-$900-$370$504-$506
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$0$0$0$0
Stock Repurch.$1,000-$292-$709-$53
Dividends Paid-$95-$93-$95-$94
Other Fin. Act.-$337-$128-$137-$112
Financing Cash Flow$568-$513-$941-$258
Forex Effect$0$0$0$0
Net Chg. in Cash$307-$456$159-$21
Supplemental Information
Beg. Cash$632$1,088$929$950
End Cash$939$632$1,088$929
Free Cash Flow$641$427$596$743
Royalty Pharma plc (RPRX) Financial Statements & Key Stats | AlphaPilot